Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03439735 | Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC | active not recruiting | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07038369 | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | active not recruiting | Phase 1 | 134 | Atavistik Bio, IncINDUSTRY | 4 | Aug 7, 2026 |
| clinicaltrials |
| NCT04766190 | DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer(DISCO) | active not recruiting | N/A | 254 | Lauren HamelOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT05721248 | STOP-HER2: Stopping Trastuzumab in HER2+ MBC | active not recruiting | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05814354 | SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial | active not recruiting | Phase 3 | 551 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT00579488 | Clinical Significance of Germline BRCA Mutations | active not recruiting | — | 13,320 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02798341 | The Breast Program - Translational Cancer Resource(TRACR) | active not recruiting | — | 4,000 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05309655 | Cardiac Outcomes With Near-Complete Estrogen Deprivation(CROWN) | active not recruiting | N/A | 90 | Duke UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05458284 | The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment | active not recruiting | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | active not recruiting | Phase 3 | 608 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT03351348 | Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control | active not recruiting | Phase 3 | 165 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03742102 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer(BEGONIA) | active not recruiting | Phase 1 / Phase 2 | 243 | AstraZenecaINDUSTRY | 6 | Aug 4, 2026 | clinicaltrials |
| NCT06380660 | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 298 | Acerand Therapeutics (Shanghai) LimitedINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03077776 | Tracking Triple-negative Breast Cancer Evolution Through Therapy(TRACERX-TNBC) | active not recruiting | N/A | 149 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04556773 | A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer(DB-08) | active not recruiting | Phase 1 | 138 | AstraZenecaINDUSTRY | 10 | Aug 3, 2026 | clinicaltrials |
| NCT04854005 | Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation | active not recruiting | — | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05806138 | A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction | active not recruiting | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741734 | Robotic-Assisted vs. Endoscopic-Assisted Sentinel Lymph Node Biopsy in Breast Cancer | active not recruiting | — | 150 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04052555 | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04345913 | Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT05715255 | Adaptive Symptom Self-Management Immunotherapy Study | active not recruiting | N/A | 400 | University of ArizonaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03168737 | 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients | active not recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05896189 | Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | active not recruiting | N/A | 386 | NRG OncologyOTHER | 2 | Jul 30, 2026 | clinicaltrials |
| NCT03304080 | Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | active not recruiting | Phase 1 / Phase 2 | 44 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06419621 | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | active not recruiting | Phase 3 | 392 | Biotheus Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06445400 | A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | active not recruiting | Phase 2 | 83 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 415 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Jul 27, 2026 | clinicaltrials |
| NCT04243616 | Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer(CemiHALT) | active not recruiting | Phase 2 | 36 | Medical College of WisconsinOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02942355 | Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04461808 | Tomosynthesis as Primary Test for Breast Cancer Screening(MAITA) | active not recruiting | N/A | 10,156 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06295744 | Outcomes and Cosmesis With Whole Breast Irradiation and Boost | active not recruiting | N/A | 50 | University of Wisconsin, MadisonOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03975647 | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | active not recruiting | Phase 3 | 466 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 20 | Jul 23, 2026 | clinicaltrials |
| NCT04595435 | IORT-Breast at Medical Center Navicent Health(IORT-Breast) | active not recruiting | — | 94 | Wake Forest University Health SciencesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05455658 | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | active not recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06316531 | A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | active not recruiting | Phase 3 | 274 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06382142 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) | active not recruiting | Phase 3 | 418 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02414269 | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | active not recruiting | Phase 1 / Phase 2 | 113 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03546686 | Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | active not recruiting | Phase 2 | 51 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03990610 | An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction | active not recruiting | N/A | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04158362 | Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer(AMBRE) | active not recruiting | Phase 3 | 180 | UNICANCEROTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04895358 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | active not recruiting | Phase 3 | 342 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Jul 22, 2026 | clinicaltrials |
| NCT04975308 | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer(EMBER-3) | active not recruiting | Phase 3 | 874 | Eli Lilly and CompanyINDUSTRY | 22 | Jul 22, 2026 | clinicaltrials |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | active not recruiting | Phase 2 | 54 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT03255577 | Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer | active not recruiting | N/A | 162 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03495011 | MRI Characterization of Mammographically Detected DCIS | active not recruiting | — | 122 | University of WashingtonOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05552001 | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer(ISIdE) | active not recruiting | Phase 3 | 96 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2026source: clinicaltrials